EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia

Sha Ma, Ying Wang, Kunming Qi, Wenyi Lu, Yuekun Qi, Jiang Cao, Mingshan Niu, Depeng Li, Wei Sang, Zhiling Yan, Feng Zhu, Hai Cheng und 3 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03661-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Sha Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neurotoxicity Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study of 67 patients with R/R B-ALL who received anti-CD19 CAR T-cell therapy, 41 (61.2%) patients received G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar duration of grade 3–4 neutropenia between the two groups. The incidences of CRS and NEs were higher in G-CSF group, while no differences in severity were found. Further stratified analysis showed that the incidence and severity of CRS were not associated with G-CSF administration in patients with low bone marrow (BM) tumor burden. None of the patients with low BM tumor burden developed NEs. However, there was a significant increase in the incidence of CRS after G-CSF administration in patients with high BM tumor burden. The duration of CRS in patients who used G-CSF was longer. There were no significant differences in response rates at 1 and 3 months after CAR T-cell infusion, as well as overall survival (OS) between the two groups. In conclusion, our results showed that G-CSF administration was not associated with the incidence or severity of CRS in patients with low BM tumor burden, but the incidence of CRS was higher after G-CSF administration in patients with high BM tumor burden. The duration of CRS was prolonged in G-CSF group. G-CSF administration was not associated with the efficacy of CAR T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeurotoxicity SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansGranulocyte Colony-Stimulating FactorImmunotherapy, AdoptiveRetrospective StudiesCytokine Release SyndromeCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

B-cell acute lymphoblastic leukemiaChimeric antigen receptor T-cell therapyCytokine release syndromeEfficacyGranulocyte colony-stimulating factorNeurotoxic events

Substanzen

Receptors, Chimeric AntigenGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
  • Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China.
  • Department of Hematology, Tianjin First Central Hospital, No. 24 Fu Kang Road, Tianjin, 300192, China.
  • Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China. lizhenyumd@163.com.
  • Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China. lizhenyumd@163.com.
  • Department of Hematology, Tianjin First Central Hospital, No. 24 Fu Kang Road, Tianjin, 300192, China. mingfengzhao@sina.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, S., Wang, Y., Qi, K., Lu, W., Qi, Y., Cao, J., Niu, M., Li, D., Sang, W., Yan, Z., Zhu, F., Cheng, H., Li, Z., Zhao, M., & Xu, K. (2024). Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03661-1

Vancouver

Ma S, Wang Y, Qi K, Lu W, Qi Y, Cao J, et al. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03661-1

BibTeX
@article{Ma2024,
  author = {Ma, Sha and Wang, Ying and Qi, Kunming and Lu, Wenyi and Qi, Yuekun and Cao, Jiang and Niu, Mingshan and Li, Depeng and Sang, Wei and Yan, Zhiling and Zhu, Feng and Cheng, Hai and Li, Zhenyu and Zhao, Mingfeng and Xu, Kailin},
  title = {Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03661-1}
}
Kostenlos starten →